Surgery Can Benefit 'Ineligible' High-Risk Lung Cancer Patients

This article originally appeared here.
Share this content:
Surgery Can Benefit 'Ineligible' High-Risk Lung Cancer Patients
Surgery Can Benefit 'Ineligible' High-Risk Lung Cancer Patients

WEDNESDAY, Nov. 11, 2015 (HealthDay News) -- One in five patients with early-stage non-small-cell lung cancer are deemed high-risk or ineligible for lung surgery, but these patients may benefit from the procedure, according to research published online Nov. 9 in the Annals of Thoracic Surgery.

The study included 490 early-stage lung cancer patients who underwent surgery between 2009 and 2013. Of those, 180 patients were classified as high risk.

High-risk patients had slightly longer hospital stays than standard-risk patients -- five days versus four days, and the postoperative mortality risk was 2 and 1 percent, respectively. Three years after surgery, 59 percent of high-risk patients and 76 percent of standard-risk patients were still alive.

"Importantly, we found that about 20 percent of our patients had cancer that had spread to their lymph nodes, a finding that was unexpected based on the preoperative imaging tests," study leader Manu Sancheti, M.D., from the Emory University School of Medicine in Atlanta, said in a journal news release. "High-risk patients have a new treatment avenue that previously may have been denied to them. A multidisciplinary team should review each case to determine the best treatment plan for individual lung cancer patients."

Abstract
Full Text (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!




Already a member?

Sign In Now »

Drug Lookup

Browse drugs by: BrandGenericDisease

More in Home

WHO: Vaccine Hesitancy a Major Global Health Threat

WHO: Vaccine Hesitancy a Major Global Health Threat

Percentage of U.S. children 19 to 35 months who have not been vaccinated has quadrupled since 2001

FDA Down to 5 Weeks of Funding to Review New Drug Applications

FDA Down to 5 Weeks of Funding to ...

Agency cannot accept new fees or applications until the shutdown is over

FDA Approves First Generic Version of Epilepsy Drug Sabril

FDA Approves First Generic Version of Epilepsy Drug ...

Generic equivalents held to same vigorous manufacturing standards as brand-name drugs

is free, fast, and customized just for you!




Already a member?

Sign In Now »